Category: piperidines

Soluble Epoxide Hydrolase Inhibition Attenuates MPTP-Induced Neurotoxicity in the Nigrostriatal Dopaminergic System: Involvement of α-Synuclein Aggregation and ER Stress was written by Huang, Hui-Ju;Wang, Yi-Ting;Lin, Hui-Ching;Lee, Yi-Hsuan;Lin, Anya Maan-Yuh. And the article was included in Molecular Neurobiology in 2018.Application of 1222780-33-7 The following contents are mentioned in the article:

Soluble epoxide hydrolase (sEH) is widely expressed in the mammalian brain and possesses dual enzymic activities, including C-terminal epoxide hydrolase (C-EH) which degrades epoxyeicosatrienoic acid (EET), a beneficial arachidonic acid metabolite. In the present study, the neuroprotective effect of sEH inhibition on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurodegeneration of nigrostriatal dopaminergic system was investigated using genetic and pharmacol. approaches. MPTP (15 mg/kg) was i.p. injected in sEH knockout (KO) mice and C57BL/6J mice as wild-type (WT) mice. Compared with the MPTP-treated WT mice, MPTP-induced reductions in striatal dopamine content and nigral tyrosine hydroxylase level (TH, a biomarker of dopaminergic neurons) were less significant in the treated sEH mice. Furthermore, MPTP-induced HO-1 elevation (a redox-regulated protein), α-synuclein aggregation, and caspase 12 activation (a hallmark of ER stress) were less prominent in sEH KO mice than in WT mice. These data indicate that sEH KO mice are more resistant to MPTP-induced neurotoxicity. The pharmacol. effect of N-[1-(1-oxopropyl)-4-piperidinyl]-N0-[4-(trifluoromethoxy)phenyl]-urea (TPPU, an sEH inhibitor) on MPTP-induced neurotoxicity was investigated in WT mice. TPPU (1 mg/kg, i.p.) attenuated MPTP-induced reduction in striatal dopamine content, TH-pos. cell numbers, TH, and pro-caspase 9 protein levels (an initiator caspase of apoptosis) in mouse SN. Moreover, TPPU reduced MPTP-induced HO-1 elevation, α-synuclein aggregation and caspase 12 activation, indicating that TPPU is effective in attenuating MPTP-induced oxidative stress, apoptosis, protein aggregation, and ER stress. In conclusion, our study suggests that sEH is a potential target for developing therapies for parkinsonism. Furthermore, sEH inhibitors may be of clin. significance for treating CNS neurodegenerative diseases. This study involved multiple reactions and reactants, such as 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7Application of 1222780-33-7).

1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea (cas: 1222780-33-7) belongs to piperidine derivatives. The piperidine ring can be found not only in more than half of the currently known structures of alkaloids, but also in many natural or synthetic compounds with interesting biological activities. Piperidine prefers a chair conformation, similar to cyclohexane. Unlike cyclohexane, piperidine has two distinguishable chair conformations: one with the N–H bond in an axial position, and the other in an equatorial position.Application of 1222780-33-7

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

New pencil graphite electrodes for potentiometric determination of fexofenadine hydrochloride and montelukast sodium in their pure, synthetic mixtures, and combined dosage form was written by Nashed, Dania;Noureldin, Imad;Sakur, Amir Alhaj. And the article was included in BMC Chemistry in 2020.Quality Control of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

This paper introduces the first electrochem. approach for the determination of Fexofenadine hydrochloride and Montelukast sodium as a combined form by constructing three new graphite electrodes coated with a polymeric membrane. The first electrode was constructed using ammonium molybdate reagent as an ion pair with fexofenadine cation for the determination of Fexofenadine drug, the second electrode was constructed using cobalt nitrate as an ion pair with montelukast anion for the determination of Montelukast drug, the third electrode was prepared by incorporating the two previously mentioned ion pairs in the same graphite sensor, which makes this sensor sensitive to each Fexofenadine and Montelukast drug. The coating material was a polymeric film comprises of Poly Vinyl Chloride (PVC), Di-Bu phthalate as a plasticizer (DBP), ion pairs of drugs with previously mentioned reagents. The electrodes showed a Nernstian response with a mean calibration graph slopes of [59.227, 28.430, (59.048, 28,643)] mv.decade-1 for the three pencil electrodes resp., with detection limits 0.025μM for Fexofenadine and 0.019μM for Montelukast drug which makes this method outperforms the reported method for the determination of this combination. The electrodes work effectively over pH range (2-4.5) for Fexofenadine hydrochloride and (5-9.5) for Montelukast sodium. The influence of the proposed interfering species was negligible as shown by selectivity coefficient values. The effectiveness of the electrodes continued in a period of time (45-69) days. The suggested sensors demonstrated useful anal. features for the determination of both drugs in bulk powder, in laboratory prepared mixtures and their combined dosage form. We have validated the method following ICH protocol, and we have reached very significant results in terms of the linearity, accuracy, selectivity, and precision of the method. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Quality Control of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.Quality Control of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice was written by Miyake, Taiji;Tsutsui, Haruka;Haraya, Kenta;Tachibana, Tatsuhiko;Morimoto, Kayoko;Takehara, Shoko;Ayabe, Miho;Kobayashi, Kaoru;Kazuki, Yasuhiro. And the article was included in British Journal of Pharmacology in 2021.Category: piperidines The following contents are mentioned in the article:

P-glycoprotein (P-gp) exhibits a broad substrate specificity and affects pharmacokinetics, especially intestinal absorption. However, prediction, in vivo, of P-gp-mediated drug-drug interaction (DDI) and non-linear absorption at the preclin. stage, is challenging. Here we evaluate the use of human MDR1 mouse artificial chromosome (hMDR1-MAC) mice carrying human P-gp and lacking their own murine P-gp to quant. predict human P-gp-mediated DDI and non-linear absorption. The P-gp substrates (aliskiren, betrixaban, celiprolol, digoxin, fexofenadine and talinolol) were administered orally to wild-type, Mdr1a/b-knockout (KO) and hMDR1-MAC mice, and their plasma concentrations were measured. We calculated the ratio of area under the curve (AUCR) in mice (AUC_Mdr1a/b-KO/AUC_wild-type or AUC_Mdr1a/b-KO/AUC_hMDR1-MAC) estimated as attributable to complete P-gp inhibition and the human AUCR with and without P-gp inhibitor administration. The correlations of AUCR_human with AUCR_wild-type and AUCRhMDR1-MAC were investigated. For aliskiren, betrixaban and celiprolol, the K_m and V_max values for P-gp in hMDR1-MAC mice and humans were optimized from different dosing studies using GastroPlus. The correlations of K_m and V_max for P-gp between human and hMDR1-MAC mice were investigated. A better correlation between AUCR_human and AUCRhMDR1-MAC (R² = 0.88) was observed Moreover, good relationships of K_m (R² = 1.00) and V_max (R² = 0.98) for P-gp between humans and hMDR1-MAC mice were observed These results suggest that P-gp-mediated DDI and non-linear absorption can be predicted using hMDR1-MAC mice. These mice are a useful in vivo tool for quant. predicting P-gp-mediated disposition in drug discovery and development. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Category: piperidines).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Several piperidine alkaloids isolated from natural herbs, were found to exhibit antiproliferation and antimetastatic effects on various types of cancers both in vitro and in vivo for example Piperine, Evodiamine, Matrine, Berberine and Tetrandine.Category: piperidines

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

A decision tree framework to support design, operation, and performance assessment of constructed wetlands for the removal of emerging organic contaminants was written by Ilyas, Huma;Masih, Ilyas;van Hullebusch, Eric D.. And the article was included in Science of the Total Environment in 2021.Recommanded Product: 83799-24-0 The following contents are mentioned in the article:

There is an increasing focus on research related to the removal of emerging organic contaminants (EOCs) from wastewater by using constructed wetlands (CWs). However, research is lacking on translating the available scientific evidence into decision support tools. In this paper, a novel decision tree framework is developed and demonstrated. The proposed framework consists of five steps: (1) generate a list of EOCs by the anal. of the wastewater; (2) select the best type of CW for each of the selected EOCs; (3) select a final type of CW for the removal of the selected EOCs; (4) identify detailed design and operational features of the proposed CW such as, depth, area, plants, support matrix, hydraulic loading rate, organic loading rate, and hydraulic retention time; and (5) assess the expected removal efficiency of EOCs in the selected CW. A novel decision support tool, named as DTFT-CW, was developed to generate data and information for the application of the proposed decision tree framework. DTFT-CW (given as a supplementary material) was developed using Microsoft Excel 2016 to support decisions on the design, operation, and performance of CWs for the removal of 59 EOCs (33 pharmaceuticals-PhCs, 15 personal care products-PCPs, and 11 steroidal hormones-SHs). The paper demonstrates the usefulness of the developed decision-making tools by considering 19 EOCs (13 PhCs, one PCPs, and five SHs) as an example, which pose high environmental risk and are on the European Union watch list (six of the 19 EOCs). An integrated design of HCW (combining vertical flow CW, horizontal flow CW-HFCW, and free water surface CW) is recommended for the treatment of multiple EOCs instead of a single type of CW such as HFCW that is most widely used in practice. The proposed tools could be useful for decision makers such as policy makers, design engineers, and researchers. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Recommanded Product: 83799-24-0).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Recommanded Product: 83799-24-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Network Pharmacology Study to Elucidate the Key Targets of Underlying Antihistamines against COVID-19 was written by Oh, Ki-Kwang;Adnan, Md.;Cho, Dong-Ha. And the article was included in Current Issues in Molecular Biology in 2022.Quality Control of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Antihistamines have potent efficacy to alleviate COVID-19 (Coronavirus disease 2019) symptoms such as anti-inflammation and as a pain reliever. However, the pharmacol. mechanism(s), key target(s), and drug(s) are not documented well against COVID-19. Thus, we investigated to decipher the most significant components and how its research methodol. was utilized by network pharmacol. The list of 32 common antihistamines on the market were retrieved via drug browsing databases. The targets associated with the selected antihistamines and the targets that responded to COVID-19 infection were identified by the Similarity Ensemble Approach (SEA), SwissTargetPrediction (STP), and PubChem, resp. We described bubble charts, the Pathways-Targets-Antihistamines (PTA) network, and the protein-protein interaction (PPI) network on the RPackage via STRING database. Furthermore, we utilized the AutoDock Tools software to perform mol. docking tests (MDT) on the key targets and drugs to evaluate the network pharmacol. perspective. The final 15 targets were identified as core targets, indicating that Neuroactive ligand-receptor interaction might be the hub-signaling pathway of antihistamines on COVID-19 via bubble chart. The PTA network was constructed by the RPackage, which identified 7 pathways, 11 targets, and 30 drugs. In addition, GRIN2B, a key target, was identified via topol. anal. of the PPI network. Finally, we observed that the GRIN2B-Loratidine complex was the most stable docking score with -7.3 kcal/mol through mol. docking test. Our results showed that Loratadine might exert as an antagonist on GRIN2B via the neuroactive ligand-receptor interaction pathway. To sum up, we elucidated the most potential antihistamine, a key target, and a key pharmacol. pathway as alleviating components against COVID-19, supporting scientific evidence for further research. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Quality Control of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. The piperidine structural motif is present in numerous natural alkaloids. These include piperine, which gives black pepper its spicy taste. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.Quality Control of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Histamine receptors rapidly desensitize without altering nerve-evoked contractions in murine urinary bladder smooth muscle was written by Jones, B. Malique;Mingin, Gerald C.;Tykocki, Nathan R.. And the article was included in American Journal of Physiology in 2022.Related Products of 83799-24-0 The following contents are mentioned in the article:

Histamine has been implicated in urinary bladder dysfunction as an inflammatory mediator driving sensory nerve hypersensitivity. However, the direct influence of histamine on smooth muscle has not been thoroughly investigated. We hypothesized that histamine directly contracts urinary bladder smooth muscle (UBSM) independent of effects on nerves. Single cell quant. RT-PCR determined that only histamine H1 and H2 receptors were expressed on UBSM cells. In isolated tissue bath experiments, histamine (200μM) caused a highly variable and rapidly desensitizing contraction that was completely abolished by the H1 receptor antagonist fexofenadine (5μM) and the Gq/11 inhibitor YM254890 (1μM). Neither the muscarinic receptor antagonist atropine (1μM), the Na+ channel blocker tetrodotoxin (1μM), nor the transient receptor potential vanilloid type 1 antagonist capsazepine (10μM) altered responses to histamine, suggesting that nerve activation was not involved. UBSM desensitization to histamine was not due to receptor internalization, as neither the cholesterol-depleting agent methyl-β-cyclodextrin (10 mM), the dynamin-mediated endocytosis inhibitor dynasore (100μM), nor the clathrin-mediated endocytosis inhibitor pitstop2 (15μM) augmented or prolonged histamine contractions. Buffer from desensitized tissues still contracted histamine-naive tissues, revealing that histamine was not metabolized. Prolonged exposure to histamine also had no effect on contractions due to elec. field stimulation, suggesting that both efferent nerve and UBSM excitability were unchanged. Together, these data suggest that histamine, although able to transiently contract UBSM, does not have a lasting effect on UBSM excitability or responses to efferent nerve input. Thus, any acute effects of histamine directly on UBSM contractility are unlikely to alter urinary bladder function. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Related Products of 83799-24-0).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Industrially, piperidine is produced by the hydrogenation of pyridine, usually over a molybdenum disulfide catalyst. Pyridine can also be reduced to piperidine via a modified Birch reduction using sodium in ethanol.Related Products of 83799-24-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Preparation of Δ¹-pyrroline-2-carboxylic acid and a new proline synthesis was written by Hasse, Kurt;Wieland, Alfred. And the article was included in Chemische Berichte in 1960.HPLC of Formula: 30727-21-0 The following contents are mentioned in the article:

2,3-Dioxopiperidine-4-carboxylic acid Et ester (I), obtained by condensation of 2-pyrrolidone (II) with (CO₂Et)₂ (III), was converted by hydrolysis to H₂N(CH₂)₃COCO₂H.HCl (IV) and this hydrogenated to yield DL-proline (V). K (10 g.) dissolved in 100 cc. absolute EtOH, the solution evaporated in vacuo, the residue dissolved in 200 cc. Et₂O, the solution treated with 25 cc. II and 50 cc. III in 50 cc. Et₂O, the mixture treated after 24 hrs. with 100 cc. 1:4 HCl, and the Et₂O phase concentrated gave 90% [EtO₂C(CH₂)₃NHCO]₂ (VI), m. 106° (H₂O or EtOH). VI (1 g.) in 5 cc. 6N HCl heated 1 hr. at 80° and concentrated gave [HO₂C(CH₂)₃NHCO]₂, m. 210°. II condensed in the usual manner with III, the mixture acidified with HCl, and the Et₂O phase evaporated in vacuo at 120° gave 3-ethoxalyl-2-pyrrolidone (VII), m. 132° (EtOH). 3-Oxalyl-2-pyrrolidone (VIII) (0.75 g.) and 20 cc. alc. HCl kept 36 hrs. at room temperature and evaporated in vacuo yielded VII, m. 131-2° (C₆H₆). VII (0.5 g.) in 5 cc. 6N HCl heated 0.5 hr. at 80° gave VIII, decomposing above 205°. K (4 g.) under 60 cc. Et₂O treated during 1 hr. with 13.8 g. absolute EtOH, warmed 3-4 hrs. on the water bath, treated at 0-5° with stirring with 14.6 g. III, the mixture treated after 10 min. during 0.5 hr. with 18.9 g. N-benzoyl-2-pyrrolidone in 27 cc. dry dioxane, diluted after 1 hr. with 150 cc. Et₂O, and filtered after 12 hrs., the residue dried in vacuo (23 g.), added with stirring to 40 cc. H₂O, 15 cc. HCl, and 30 cc. CHCl₃, the CHCl₃ phase evaporated, the residual oil dissolved at 90° with stirring during 10 min. in 40 cc. 6N HCl, and the hot solution filtered and cooled gave 2 g. VIII, needles, decomposing above 205° with sintering; the mother liquor gave 5.6 g. HO₂CCONH(CH₂)₃CO₂H, m. 163-4° (decomposition) (H₂O or Me₂CO). VIII (20.4 mg.) in 10 cc. H₂O treated with 15 cc. 1% 2,4-(O₂N)₂C₆H₃NHNH₂ in 2N HCl gave the 2,4-dinitrophenylhydrazone of VIII, m. 221° (decomposition). K (20 g.), a few crystals of iodine and a small amount of Hg₂Cl₂ in 50 cc. absolute C₆H₆ treated with 40 cc. absolute EtOH in portions, the mixture diluted with 30 cc. EtOH in 150 cc. C₆H₆, warmed slightly, diluted further with 300 cc. C₆H₆, treated with 43 g. II and 73 g. III, refluxed 18 hrs. with stirring, and treated with 80 cc. 6N HCl, the hot C₆H₆ layer decanted, the aqueous phase extracted with C₆H₆, and the combined C₆H₆ solutions worked up yielded 80% I, m. 148°. I (370 mg.) in EtOH hydrogenated at 20°/760 mm. over PtO₂, filtered, and evaporated gave 3-hydroxy-4-carbethoxy-2-piperidone, m. 121-2° (C₆H₆). I (5.3 g.) and 80 cc. 6N HCl refluxed 6 min. (in larger runs 20 min.) and evaporated at 35°/12 mm., and the residue refrigerated several hrs., filtered, washed with cold HCl, and dried yielded IV, m. 113° (HCl-AcOH-Et₂O). VIII (1.03 g.) and 35 cc. 6N HCl refluxed 1 hr. and evaporated at 35°/16 mm., the residue dissolved in H₂O and chromatographed on Dowex 50-X-8 (H form), and the fractions from 207-358 cc. evaporated gave 0.7 g. IV, m. 113° (decomposition). IV (48.7 mg.) hydrogenated 3 hrs. at 21°/755 mm. over PtO₂, filtered, treated with Ag₂O and then H₂S, refiltered, and evaporated, and the residue and 48 mg. picric acid dissolved in hot glacial AcOH and diluted with Et₂O gave the picrate of V, m. 134-5°. I (12.5 g.) and 200 cc. 6N HCl refluxed 7 min., concentrated at 40°/25 mm. to 30 cc., diluted with 120 cc. H₂O, hydrogenated 5 hrs. at 25°/1 atm. over 270 mg. PtO₂, filtered, placed on Amberlite IR-4B, washed with 1.3 l. H₂O, and eluted gave 5.51 g. pure V. This study involved multiple reactions and reactants, such as Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0HPLC of Formula: 30727-21-0).

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives.Piperidine is a key saturated heterocyclic scaffold found in several of the top-selling small molecule pharmaceuticals and natural alkaloids, with a diverse range of biological activities. Some chemotherapeutic agents have piperidine moiety within their structure, foremost among them, vinblastine and raloxifene.HPLC of Formula: 30727-21-0

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Acyl-lactone rearrangement. XXIII. Syntheses of cyclic amino acids by the reaction principle of the acyl-lactone rearrangement was written by Buechel, Karl Heinz;Korte, Friedhelm. And the article was included in Chemische Berichte in 1962.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate The following contents are mentioned in the article:

3-Ethoxalyl-2-pyrrolidones and 3-ethoxalyl-2-piperidones were converted by heating with decarboxylation and rearrangement and by subsequent catalytic hydrogenation to DL-hygrinic acid (I), DL-proline (II), and DL-N-methylpipecolinic acid (III), resp., in high yields. N-Methyl-2-pyrrolidone and (CO₂Et)₂ (IV) were condensed with coarsely cut and with powd. K to yield 56 and 60-65%, resp., 3-ethoxalyl-N-methyl-2-pyrrolidone (V). V (1 g.) in 25 cc. concentrated HCl refluxed 20 hrs., concentrated in vacuo, diluted with 20 cc. H₂O, treated with 1 g. 2,4-(O₂N)₂C₆H₃NHNH₂ in 170 cc. 2N HCl, and kept several days gave the 2,4-dinitrophenylhydrazone of MeNH(CH₂)₃-COCO₂H, m. 183-4° (2N HCl). V (10 g.) in 60 cc. concentrated HCl refluxed 20 hrs. until the maximum at 285 mμ had disappeared, concentrated to 50 cc., cooled, filtered, from 0.1-0.3 g. V, diluted with H₂O, hydrogenated over 0.5 g. PtO₂, filtered, and evaporated, and the residual I.HCl (9 g.) dissolved in H₂O, passed through weakly basic Duolite A 7, and evaporated gave I, m. 174-5° (EtOH-Et₂O); I.HCl m. 183-5° (EtOH-Et₂O). 2-Pyrrolidone heated with excess Ac₂O gave 95% N-Ac derivative (VI), b₁₂ 109-10°. VI (127 g.) and 204 g. IV in 100 cc. dry Et₂O added dropwise at -5 to 0° to 39.1 g. powd. K and 1 cc. absolute EtOH in 400 cc. dry Et₂O, stirred 8 hrs., added with stirring and cooling to 500 cc. 2N HCl, and extracted with CHCl₃ gave 209 g. (crude) 3-ethoxalyl-N-acetyl-2-pyrrolidone (VII), b_0.05 90-5°, blue-violet with FeCl₃; the higher boiling fractions deposited 3-ethoxalyl-2-pyrrolidone, m. 134-6° (ligroine), blue with FeCl₃. Crude VII (5 g.) and 20 cc. 6N HCl heated 24 hrs. at 60° gave 1.2 g. 3-oxalyl-2-pyrrolidone, m. 208-10° (decomposition). VI (127 g.) and 180 g. IV added dropwise with stirring to 39.1 g. K and 1 cc. absolute EtOH in 400 cc. dry MePh at about 100° and worked up in the usual manner yielded 160 g. (crude) [EtO₂C(CH₂)₃NHCO]₂ (VIII), needles, m. 103-6° (ligroine, b. 80-110°). VIII refluxed with 6N HCl gave [HO₂C-(CH₂)₃NHCO]₂, m. 212°. The brown semisolid residue from the mother liquor from VIII treated in EtOH with C, concentrated, and diluted with petr. ether gave 26 g. 2,3-dioxo-4-carbethoxypiperidine, m. 148° (C₆H₆), ruby-red with FeCl₃. VII (22.7 g.) in concentrated HCl refluxed 1 hr., concentrated to half-volume, diluted with an equal volume H₂O, hydrogenated over 0.5 g. PtO₂, and worked up, and the residual crude II.HCl dissolved in H₂O, passed through Duolite A 7, eluted with 1.5 l. H₂O, and evaporated yielded 9 g. II, m. 214-15°. VII treated in the usual manner with 2,4-(O₂N)₂C₆H₃NH-NH₂ yielded the 2,4-dinitrophenylhydrazone of H₂N(CH₂)₃-COCO₂H, yellow, m. 217-18° (2N HCl). α-Ethoxalyl-N-methyl-2-piperidone (21.3 g.) added to 100 cc. boiling 6N HCl, refluxed about 5 min., concentrated to about 40 cc., diluted with an equal volume H₂O, hydrogenated over 0.5 g. PtO₂, and worked up yielded 17.9 g. III.HCl, m. 195-200°. III.HCl in H₂O treated with Amberlite 4-B and evaporated gave 14.0 g. III, m. 208-10° (EtOH-Et₂O). III treated in the usual manner with 2,4-(O₂N)₂C₆H₃-NHNH₂ gave the 2,4-dinitrophenylhydrazone of MeNH(CH₂)₄-COCO₂H, yellow needles, m. 207° (2N HCl). III (2.9 g.) in MeOH methylated with MeI-Ag₂O yielded DL-homostachydrine (IX), very hygroscopic crystals, m. 207-8° (EtOH-Et₂O); IX.-HCl, m. 211° (EtOH-Et₂O). This study involved multiple reactions and reactants, such as Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0Name: Ethyl 2,3-dioxopiperidine-4-carboxylate).

Ethyl 2,3-dioxopiperidine-4-carboxylate (cas: 30727-21-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Name: Ethyl 2,3-dioxopiperidine-4-carboxylate

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

Evaluation of efficacy of Levocetrizine, Fexofenadine and their combination with monteleukast in allergic rhinitis in Jharkhand, India was written by Priyanki;Kumar, Pramveer;Kumari, Kusum;Ragini, Kavita;Chandra, Satish;Kumar, Sandeep;Gari, Manju. And the article was included in World Journal of Pharmacy and Pharmaceutical Sciences in 2021.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid The following contents are mentioned in the article:

Allergic Rhinitis is the most common of all atopic diseases. It is an important public health problem. It affects 20-25% of world population. The most common pharmacol. treatment options include intranasal corticosteroids, antihistamines, Leukotriene (LT) pathway inhibitor, α-adrenergic agonist, etc. Here, we aim to compare the efficacy of Levocetrizine and Fexofenadine and also, to compare the efficacy of Levocetrizine + Montelukast and fexofenadine + Montelukast in the treatment of allergic rhinitis in a tertiary hospital in Jharkhand, India. This observational follow up study was conducted in the department of pharmacol. & Therapeutics, among the patient attending out patient department of Ear, Nose and Throat (ENT) of Rajendra Institute of Medical Sciences, Ranchi, Jharkhand with prior approval from Institutional ethics committee. Observational, single centered, randomised, open label, four arm, parallel-group, comparative clin. study. 110 Patients were enrolled who have met the inclusion criteria for the study from the OPD of ENT Department of RIMS during the study period. The patients were placed in four groups and received their resp. medication orally once daily in the evening for period of two weeks. On the day of the participant enrolment, a written informed consent was taken from all the patient, medical history, phys. examination, patient′s symptoms recorded on TNSS Sheet (Total Nasal Symptoms Score) and demonstrated to subject how to note and hand over the TNSS Sheet. After Completion of study on 15^th day, phys. examination and vital sign were checked; recording on sheet was collected. Mean changes in TNSS at the end of 24 h, 1^st and 2^nd week and comparison of effect of drugs with and without montelukast with the help of Total Nasal Score were calculated by using Statistical Package for the Social Sciences, IBM SPSS 20. The data was tabulated as mean ± standard deviation (Mean SD). Paired′t′ test was used to compare mean changes in TNSS Score before and after treatment. Out of total 110 enrolled patients, 98 completed the study, 4 patients not completed 2weeks treatment, 2 patients had change in disease pattern and 6 patient lost to follow up. The demog. characteristics of four groups were compared for age and sex. All groups had female predominance. The baseline Total Nasal Symtoms Score (TNSS) were comparable among the all four treatment groups. The mean TNSS was significantly reduced in all four study groups. After 1day of treatment change in TNSS have in following order Group C > Group D >Group A >Group B. Maximum change was observed in Levocetrizine & Montelukast combination group and min. change was observed in Fexofenadine group. Same order of change in TNSS was observed in study after 1 wk and 2weeks of treatment. So in our study Levocetrizine have been found better than fexofenadine in decreasing TNSS in allergic rhinitis patient. Similarly Levocetirizine-Montelukast combination decreases TNSS more than Fexofenadine-Montelukast combination. All the study drugs have shown significant improvement in quality of life of Allergic rhinitis patients. Levocetrizine has shown more effectiveness than Fexofenadine when used alone in allergic rhinitis patient. Levocetrizine-montelukast combination shows better effect than Fexofenadine-Montelukast combination drugs. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine and its derivatives have become increasingly popular in many synthetic schemes. Piperidine derivatives bearing a masked aldehyde function in the ε-position are easily transformed into quinolizidine compounds through intramolecular reductive amination.Application In Synthesis of 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem

A study on prescription pattern of chronic kidney disease in tertiary care hospital was written by Saraswathi Pravallika, M.;Sampreethi, H.;Anusha, C. H.;Rohini, K.;Shete, Shivkumar. And the article was included in European Journal of Biomedical and Pharmaceutical Sciences in 2021.Electric Literature of C32H39NO4 The following contents are mentioned in the article:

The aim of the present investigation is to study the prescription pattern of chronic kidney disease in tertiary care hospital. The objective of the study was to study the prescription patterns of drugs used in chronic kidney disease and other comorbid conditions and to identify which drug is mostly prescribed at that hospital. To assess the rationality of prescription. To evaluate the medication adherence in CKD patients. The study on prescribing pattern definitely improves the quality of prescription writing, so study of drug prescribing pattern is relevant in the present scenario. To evaluate the prevalence of correct dosing in chronic kidney diseases depending on renal function estimation This is a retrospective, prospective observational study conducted over a period of six months. The study was conducted at Medicine ward of GLENEAGLES AWARE GLOBAL HOSPITAL LB.NAGAR. Patients who admitted to Nephrol. department of the hospital during a six- month period from Oct. 2021 to March 2021 are enrolled. CKD patients visiting the nephrologists are evaluated, diagnosed and prescribed with suitable therapy. All necessary details were collected from patient demographics, prescription chart, lab data, progress chart, medical records, doctor’s notes, nursing notes using a suitable designed data collection form. One hundred one patients were included in the project; with a mean age of 62.5. ± 18 years. More than half of patients were male, 77(76.2%). The mean BMI was 26 ± 1.15 kg/ m². The majority of patients were having normal weight 80 (79.2%), 15 (14.8%) patients had overweight, and obesity and only 6 (5.9%) patients were underweight. While 35 (34.6%) patients were smokers, 10 (9.9%) were ex-smokers and 56 (55.4%) patients were non- smokers. Anti- hypertensive agents are predominantly used among the patients. The most preferred options were beta blockers, calcium channel blockers and diuretics. Most of the physicians prescribed metoprolol (18.2%), amlodipine (38.3%), and cilnidipine (2%). Diuretics were the preferred option by the physician furosemide (92.3%), anti-platelets that are prescribed by the physicians are Aspirin (69.2%), clopidogrel (30.7%). Among the lipid lowering agents, atorvastatin (92.8%) was given to the most of the patients. sulbactam (20.4%), cefoperazone (20.4%), clarithromycin (10.25%), amoxycillin (10.25%) were mostly prescribed antibiotics in the study. The study concluded that most of the patients included in the study were suffering from chronic kidney disease. These may be due to their food habits, smoking, less exercise and poor health hygiene. The maximum number of patients was male; it may be due to smoking and alc. habits. Comorbidities such as hypertension, hyperglycemia, albuminuria, renal structure, and sex hormones, have been reported to have different effects on males and females. Thus, CKD progression may differ depending on sex. Early recognition with timely initiation of treatment in collaboration with nephrologists will improve the care for CKD patients. Thus, physicians and Nephrologists play an important outcome in patients with CKD. This study involved multiple reactions and reactants, such as 2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0Electric Literature of C32H39NO4).

2-(4-(1-Hydroxy-4-(4-(hydroxydiphenylmethyl)piperidin-1-yl)butyl)phenyl)-2-methylpropanoic acid (cas: 83799-24-0) belongs to piperidine derivatives. Piperidine is a saturated organic heteromonocyclic parent, an azacycloalkane, a secondary amine and a member of piperidines. Fluorinated piperidines are also the subject of continued interest in medicinal chemistry, for example in the synthesis of selective dipeptidyl peptidase II (DPP II) inhibitors. Piperidine derivatives are also used in solid-phase peptide synthesis (SPPS) and many degradation reactions.Electric Literature of C32H39NO4

Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem